MediGene AG
Biotechnology
-
Short facts
-
- Research & Development
- Year founded 1994
- 102 Employees (site)
- Turnover: <5m EUR
Products/services: With Eligard® for the treatment of prostate cancer, MediGene is the first German biotech company with a drug on the market. Submission of the New Drug Application for the second drug, Polyphenon® E Ointment for the treatment of genital warts, is scheduled for 2005. Apart from that, several drug candidates are currently undergoing clinical development.
Basic data
Company
MediGene AG
Street
Lochhamer Str. 11
PC / City
82152 Planegg
County
Upper Bavaria
Phone
+49 89 856529-0
Fax
+49 89 856529-20
Homepage
Language skills
English, German
Contact person
Sales / marketing: Kerstin Langlotz (Mrs.)
Management: Dr. Frank Mathias (Mr.)
Management: Peter Llewellyn-Davies (Mr.)
Profile/competences
Core competencies
MediGene's core competence is research into and development of novel approaches to the treatment of various tumor diseases (oncology). It is MediGene's strategy to integrate all core divisions of a biopharmaceutical company from research and development to commercialization of drugs.
Key sectors / sub-sectors
- Biotechnology: Preclinical development
- Biotechnology: Therapeutic drug development
NACE industries
- Research and experimental development on biotechnology 72.11
- Manufacture of basic pharmaceutical products 21.10
- Manufacture of pharmaceutical preparations 21.20
- Manufacture of medical and dental instruments and supplies 32.50
Certifications
not available
Sales markets - target industries
not available
Sales markets - target countries
not available
Cooperation offers
not available